维普期刊资源整合服务平台（V6.5）

36篇 您的检索式：作者名="Elashoff R"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Cyclophosphamide versus placebo in scleroderma lung disease显示文摘	Tashkin DP Elashoff R Clements PJ		0，，25：	1
2	Sclerodermalung study (SLS): differences in the presentation andcourse of patients with limited versus diffuse systemicsclerosis显示文摘	Clements PJ Roth MD Elashoff R	2007	Ann Rheum Dis2007，66，12：	1
3	Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease显示文摘	Tashkin DP Elashoff R Clements PJ	2007	Am J Respir Crit Care Med2007，176，10：	1
4	Effects of l-year treatment with cyclophosphamide on out comes at 2 years in scleroderma a lung disease显示文摘	Tashkin D P Elashoff R Clements P J		0，，：	1
5	Effects of I-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung dis画 ease显示文摘	Tashkin DP Elashoff R Clements PJ		Am J Respir Crlt Care0，176，10：	1
6	, Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients显示文摘	Rosenberg S Elashoff M R Beineke P	2010	Annlnternal Med2010，153，7：	1
7	Cyclophosphamide versus placebo in scleroderma lung disease显示文摘	Tashkin DP Elashoff R Clements PJ	2006	N Engl J Med2006，354，25：	1
8	Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease显示文摘	Tashkin DP Elashoff R Clements PJ	2007	Am J Respir Crit Care Med2007，176，10：	1
9	Cyclophosphamide versus placebo in scleroderma lung disease显示文摘	Tashkin DP Elashoff R Clements PJ	2006	N Engl J Med2006，354，25：	1
10	Cyclophosphamide versus placebo in scleroderma lung disease 显示文摘	Tashkin DP Elashoff R Clements PJ	2006	N Engl J Med2006，354，25：	1
11	Multi-center validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructivecoro-nary artery disease in nondiabetic patients显示文摘	Rosenberg S Elashoff M R Beineke P	2010	Annals of Internal Medicine2010，153，7：	1
12	Long- term morbidity of node biopsy versus complete, axil- lary dissection for unilateral breast cancer 显示文摘	Crane-Okada R Waseher R A Elashoff D	2008	An- nals of Surgical Ontology2008，15，7：	1
13	Effects of 1-year treatment with eyclophosphamide on out comes at 2 years in scleroderma a lung disease显示文摘	Tashkin D P Elashoff R Clements P J	2007	Am J Respir Crit Care Med2007，176，10：	1
14	Cyclophosphamide ver-sus placebo in scleroderma lung disease 显示文摘	Tashkin DP Elashoff R Clements PJ	2006	N Engl J Med2006，354，：	1
15	Effects of 1 -year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease 显示文摘	TASHKIN D P ELASHOFF R CLEMENTS P J	2007	Am J Respir Crit Care Med2007，176，10：	1
16	Effects of 1-year treat-ment with cyclophosphamide on outcomes at 2 years in sclerodermalung disease 显示文摘	Tashkin DP Elashoff R Clements PJ	2007	Am J Respir Crit Care Med2007，176，：	1
17	A critical analysis ofthe clinical use of incretin-based therapies: are the GLP-1 thera-pies safe? 显示文摘	Butler PC Elashoff M Elashoff R	2013	Diabetes Care2013，36，7：	1
18	Cyclophosphamide versus placebo in scleroderma lung disease 显示文摘	Tashkin DP Elashoff R Clements PJ	2006	N Engl J Med2006，354，25：	1
19	Missing observations in multivariate statistics I: Review of the literature显示文摘	Afifi A A Elashoff R M	1966	Journal of the American Statistical Association1966，61，315：	1
20	Cyclophosphamide versus placebo in scleroderma lung disease显示文摘	Tashkin DP Elashoff R Clements PJ		0，，25：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示